FDA grants rare pediatric disease designation to iECURE's GTP-506 for OTC deficiency
Aug. 24, 2022
The FDA has granted rare pediatric disease designation to iECURE's lead product candidate GTP-506 for the treatment of ornithine transcarbamylase (OTC) deficiency in a pediatric population.
